Skip to main content

LENZ Therapeutics, Inc.

LENZ
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001815776

No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding LENZ Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of LENZ: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders6667+1
Shares31.2M30.6M−679.1K (−2.2%)
Value$81.2M$75.8M−$5.47M (−6.7%)

New holders (12)

Institutions that held LENZ Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to LENZ in Q3 2023
InstitutionSharesValue% of portfolio
Newtyn Management, LLC542,637$1.35M0.33%
Corsair Capital Management, L.P.45,862$113.7K0.04%
BBR Partners, LLC36,722$91.1K0.01%
HSBC Holdings PLC21,755$52.2K0.00%
Landscape Capital Management, L.L.C.18,074$44.8K0.01%
XTX Topco Ltd14,398$35.7K0.01%
Susquehanna International Group, LLP13,828$34.3K0.00%
SG Americas Securities, LLC12,318$31.0K0.00%
Nisa Investment Advisors, LLC4,310$10.7K0.00%
Red Tortoise LLC639$1.58K0.00%
EverSource Wealth Advisors, LLC239$5930.00%
Simplex Trading, LLC186$00.00%

Sold out (11)

Institutions that held LENZ Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of LENZ in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Federated Hermes, Inc.408,157$1.06M
Verition Fund Management LLC229,249$596.0K
Cormorant Asset Management, LP199,547$518.8K
Western Standard LLC175,083$455.2K
BML Capital Management, LLC152,291$396.0K
Diametric Capital, LP36,302$94.4K
Annandale Capital, LLC17,930$47.0K
Laurion Capital Management LP12,204$31.7K
Erste Asset Management GmbH11,900$30.8K
State of Wyoming255$663
Acadian Asset Management LLC227$0